VIVORYON THERAPEUTICS NV (VVY.AS) Stock Fundamental Analysis

Europe • Euronext Amsterdam • AMS:VVY • NL00150002Q7

1.432 EUR
-0.02 (-1.24%)
Last: Feb 5, 2026, 04:59 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VVY. VVY was compared to 84 industry peers in the Biotechnology industry. While VVY seems to be doing ok healthwise, there are quite some concerns on its profitability. VVY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year VVY has reported negative net income.
  • VVY had a negative operating cash flow in the past year.
  • VVY had negative earnings in each of the past 5 years.
  • VVY had a negative operating cash flow in each of the past 5 years.
VVY.AS Yearly Net Income VS EBIT VS OCF VS FCFVVY.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • VVY's Return On Assets of -194.47% is on the low side compared to the rest of the industry. VVY is outperformed by 88.10% of its industry peers.
  • VVY has a Return On Equity of -392.42%. This is in the lower half of the industry: VVY underperforms 64.29% of its industry peers.
Industry RankSector Rank
ROA -194.47%
ROE -392.42%
ROIC N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
VVY.AS Yearly ROA, ROE, ROICVVY.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VVY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VVY.AS Yearly Profit, Operating, Gross MarginsVVY.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • VVY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VVY remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for VVY has been increased compared to 5 years ago.
  • The debt/assets ratio for VVY is higher compared to a year ago.
VVY.AS Yearly Shares OutstandingVVY.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
VVY.AS Yearly Total Debt VS Total AssetsVVY.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -35.96, we must say that VVY is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -35.96, VVY is doing worse than 82.14% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that VVY is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.00, VVY belongs to the best of the industry, outperforming 86.90% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.96
ROIC/WACCN/A
WACC7.44%
VVY.AS Yearly LT Debt VS Equity VS FCFVVY.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • VVY has a Current Ratio of 4.04. This indicates that VVY is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of VVY (4.04) is better than 76.19% of its industry peers.
  • A Quick Ratio of 4.04 indicates that VVY has no problem at all paying its short term obligations.
  • The Quick ratio of VVY (4.04) is better than 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 4.04
VVY.AS Yearly Current Assets VS Current LiabilitesVVY.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • VVY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
  • Looking at the last year, VVY shows a very strong growth in Revenue. The Revenue has grown by 100.00%.
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 121.74% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.5%
EPS Next 2Y22.01%
EPS Next 3Y12.69%
EPS Next 5Y121.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VVY.AS Yearly Revenue VS EstimatesVVY.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2023 2029 2030 0 500M 1B 1.5B
VVY.AS Yearly EPS VS EstimatesVVY.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VVY. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVY.AS Price Earnings VS Forward Price EarningsVVY.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVY.AS Per share dataVVY.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • VVY's earnings are expected to grow with 12.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.01%
EPS Next 3Y12.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VVY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIVORYON THERAPEUTICS NV

AMS:VVY (2/5/2026, 4:59:27 PM)

1.432

-0.02 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-04
Earnings (Next)04-27
Inst Owners10.71%
Inst Owner ChangeN/A
Ins Owners10.84%
Ins Owner ChangeN/A
Market Cap42.40M
Revenue(TTM)N/A
Net Income(TTM)-12.48M
Analysts85.71
Price Target5.95 (315.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.69%
PT rev (3m)13.82%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.33
P/tB 18.04
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.11
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -194.47%
ROE -392.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 4.04
Altman-Z -35.96
F-Score2
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)105.74%
Cap/Depr(5y)75.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
EPS Next Y49.5%
EPS Next 2Y22.01%
EPS Next 3Y12.69%
EPS Next 5Y121.74%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.44%
EBIT Next 3Y9.89%
EBIT Next 5YN/A
FCF growth 1Y67.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.04%
OCF growth 3YN/A
OCF growth 5YN/A

VIVORYON THERAPEUTICS NV / VVY.AS FAQ

What is the ChartMill fundamental rating of VIVORYON THERAPEUTICS NV (VVY.AS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS.


What is the valuation status of VIVORYON THERAPEUTICS NV (VVY.AS) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIVORYON THERAPEUTICS NV (VVY.AS). This can be considered as Overvalued.


Can you provide the profitability details for VIVORYON THERAPEUTICS NV?

VIVORYON THERAPEUTICS NV (VVY.AS) has a profitability rating of 0 / 10.


How financially healthy is VIVORYON THERAPEUTICS NV?

The financial health rating of VIVORYON THERAPEUTICS NV (VVY.AS) is 4 / 10.